Drug
ANAVEX2-73
ANAVEX2-73 is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 5 completed trials
Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_3
1
20%
Ph phase_2
4
80%
Phase Distribution
0
Early Stage
4
Mid Stage
1
Late Stage
Phase Distribution5 total trials
Phase 2Efficacy & side effects
4(80.0%)
Phase 3Large-scale testing
1(20.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
5 of 5 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(5)
Detailed Status
Completed5
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 24 (80.0%)
Phase 31 (20.0%)
Trials by Status
completed5100%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_2
OLE of Phase 2b/3 Study ANAVEX2-73-AD-004
NCT04314934
completedphase_2
OLE Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001
NCT04575259
completedphase_3
ANAVEX2-73 Study in Patients With Rett Syndrome
NCT03941444
completedphase_2
Study of ANAVEX2-73 in Patients With Rett Syndrome
NCT03758924
completedphase_2
An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease
NCT02756858
Clinical Trials (5)
Showing 5 of 5 trials
NCT04314934Phase 2
OLE of Phase 2b/3 Study ANAVEX2-73-AD-004
NCT04575259Phase 2
OLE Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001
NCT03941444Phase 3
ANAVEX2-73 Study in Patients With Rett Syndrome
NCT03758924Phase 2
Study of ANAVEX2-73 in Patients With Rett Syndrome
NCT02756858Phase 2
An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5